Taysha Gene Therapies ROE 2020-2024 | TSHA

Current and historical return on equity (ROE) values for Taysha Gene Therapies (TSHA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Taysha Gene Therapies ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-09-30 $-0.02B $0.09B -28.13%
2024-06-30 $-0.11B $0.11B -241.27%
2024-03-31 $-0.12B $0.05B -1097.67%
2023-12-31 $-0.11B $0.08B 1723.08%
2023-09-30 $-0.22B $-0.05B 860.00%
2023-06-30 $-0.13B $-0.04B 1250.00%
2023-03-31 $-0.13B $-0.02B -1786.67%
2022-12-31 $-0.17B $0.00B -691.67%
2022-09-30 $-0.16B $0.01B -338.95%
2022-06-30 $-0.19B $0.03B -231.97%
2022-03-31 $-0.19B $0.05B -162.71%
2021-12-31 $-0.17B $0.10B -108.07%
2021-09-30 $-0.14B $0.14B -71.00%
2021-06-30 $-0.11B $0.19B -45.69%
2021-03-31 $-0.09B $0.22B -46.36%
2020-12-31 $-0.06B $0.25B -45.47%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00